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An ongoing focus of  pharmaceutical research is enhancing the efficacy of  inhaled 
drugs indicated to treat lower respiratory infections. To achieve this, an inhaled drug 
must exhibit a high aerosolisation performance, or the ability of  fine particles to 
disperse and reach the target site in the lower respiratory passageways. Proper 
deposition of  the aerosol particles at the site of  action is dependent upon chemical 
properties and the aerodynamic diameter. Preliminary data demonstrated that the 
aerosolisation performance of  colistin, a hydroscopic antibiotic, notably decreased 
when stored at a relative humidity (RH) of  75% due to moisture absorption. To 
prevent moisture absorption, my aim is to combine two antibiotics, colistin and 
azithromycin, into one formulation to improve the combination drug’s delivery to the 
target site of  action and produce a synergistic effect. The use of  azithromycin, an 
antibiotic that exhibits hydrophobic properties, would minimize water absorption and 
increase the drug’s efficacy. A better understanding of  colistin and azithromycin’s 
aerosolisation properties is important in strengthening therapeutic methods to treat 
individuals with specific pulmonary disorders. 




We hypothesize that encapsulating colistin with azithromycin will improve drug 
stability by preventing moisture absorption, and therefore, enhance dispersion to the 
target site and overall aerosolisation performance. 
Thank you to the sponsors of  LSAMP. Special thanks to Nivedita Shetty, Patricia 
Ahn, and Dr. Zhou for their patience, guidance, and mentoring. 
Results
1) Optimize spray-drying process for 3-fluid nozzle by manipulating three 
independent variables: flow rate, inlet temperature, and feed concentration
2) Understand the mixing behavior with 3-fluid nozzle
2) Next Generation Impactor (NGI)
Research Goal
Figure 3: A 3-fluid nozzle spray drying system consists of  three separate channels, one each for 
the 1) core, 2) shell liquid, and 3) atomising gas. The shell and core liquids arrive at the tip of  the 
nozzle to form a concentric liquid, which is atomized and dried by hot gas to produce the core-
shell microcapsules.[6]
Spray drying is a dehydration process in which a liquid is converted to a powder 
form. Compressed air atomizes the solution into fine droplets, followed by a rapid 
drying process by hot gas, resulting in a fine powder.[6]
1) Spray Drying (Colistin:Azithromycin, 1:1)
An important factor influencing lung deposition and the efficacy of  inhaled drugs is 
particle size, or aerodynamic diameter (um). In regards to particle size, the FPF value, 
or fine particle fraction, is the value of  interest, and it is the fraction of  the total drug 
dose < 5.0 um.[2] Our research goal is to obtain an FPF value of  > 50%. 
Figure 2 (above): Distribution of  radiolabeled powder 
aerosols of  mannitol in the lungs using single photon 
emission tomography (SPECT).[1]
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The NGI measures in-vitro aerosol performance and is used to classify aerosol particles 
into size fractions for testing dry powder inhalers. Essentially, this device mimics the 
human respiratory system and consists of  8 stages, with the early stages representing the 
upper airways (stage 1: human throat) and the latter stages mimicking the lower airways 
(stage 8: alveoli of  lungs). Air passes through the impactor, and particle sizing is achieved 
by forcing the air stream through a series of  nozzles containing progressively reducing jet 
diameters. The fine particles from each stage are collected in a series of  collection cups.[5]
Figure 4: Larger particles with a greater 
aerodynamic diameter will deposit in the 
earlier stages while the smallest particles will 
deposit in the latter stages, specially in 
MOC, a collection cup that captures 
extremely small particles.[3]
3) High-performance liquid chromatography (HPLC)
HPLC is performed to separate, identify, and quantify the mixture of  azithromycin 
and colistin. A pump forces the mixture through a column under high pressure. 
Azithromycin and colistin are separated from one another due to different 
interactions with the stationary phase or column material. Each component 
possesses a distinct retention time, or the time it takes for a  solute to pass through 
the column. The computer output displays a series of  peaks, each one representing a 
component in the mixture passing through the detector and absorbing UV light.[4]
Figure 1 (left): Particles  with aerodynamic sizes 1-5 um will 
mostly deposit in the lower airways, while particles with 
aerodynamic sizes > 5 um will normally deposit in the upper 
airways due to inertial impaction.[1]
The graphs suggest azithromycin in combination with colistin successfully 
prevented moisture absorption due to no significant changes in FPF values as RH 
increased. In other words, the combination of  azithromycin and colistin improved 
drug stability at greater humidity levels and overall aerosolisation performance. 
Furthermore, the data suggest that rather than coating colistin, azithromycin acts to 
minimize the interfacial tension between colistin and water particles, ultimately 
preventing aggregation. 
Figure 9 (right):
Results produced from 
SEM (scanning electron 
microscopy) depict small 
particles adhesive to 
larger particles. The small 
particles represent 
azithromycin 
surrounding the colistin 
core, the larger particle.
Figure 7 (above) : Eleven different 
formulations were performed with 
varying flow rates, inlet 
temperatures, and feed 
concentrations. 
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Figure 8 (left): The graphs show 
there was no significant difference 
in the FPF values when optimal 
formulation #3 was exposed to 
20% RH for 24 hours and 75% RH 
for 24 hours.
Figure 6 (left): The two graphs display the 
values for emitted dose (% of  drug emitted 
from capsule and device that is deposited in the 
throat and 8 stages) and the values for FPF, 
which surpassed the target goal of  50%. The 
optimal formulation was selected based on the 
FPF value and percent yield. 
